Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2011-10-04 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2011-10-04 English
Regulatory Filings 2011
Regulatory Filings
2011-10-03 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by NeoStem, Inc. It details terms of a stock purchase agreement, risk factors, use of proceeds, and company overview. This type of document is a registration statement/prospectus supplement used in capital raising activities, specifically describing a financing transaction. It is not an annual or quarterly report, earnings release, or management discussion. It is not a proxy, governance, or legal filing. The key indicator is the presence of a prospectus supplement and registration statement language, which aligns with capital/financing update filings. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2011-09-30 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the termination of a previous Common Stock Purchase Agreement and the entry into a new Common Stock Purchase Agreement with Aspire Capital Fund, LLC, including detailed terms of the new financing arrangement. This is an update on the company's financing activities and capital structure changes. There are no financial statements or comprehensive financial data presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy, earnings release, or management discussion. The document is clearly an update on capital raising and financing agreements, fitting the definition of a Capital/Financing Update (CAP). The length and detail confirm it is the actual filing of the agreement, not just an announcement of a report publication or a regulatory filing of a certification. Therefore, the correct classification is CAP with high confidence.
2011-09-30 English
OWNERSHIP DOCUMENT
Director's Dealing
2011-09-19 English
FORM 424B3
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a joint proxy statement/prospectus related to the merger of NeoStem, Inc. and Amorcyte, Inc. It includes detailed information about the merger agreement, voting proposals for stockholders, risk factors, and recommendations from the boards of directors. The presence of voting proposals, meeting notices, and detailed merger information indicates this is a proxy solicitation document intended to inform shareholders and solicit their votes on merger-related matters. The document is not a financial report, earnings release, or regulatory filing but rather a solicitation of shareholder votes with detailed merger information. Therefore, the appropriate classification is Proxy Solicitation & Information Statement (PSI).
2011-09-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.